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sents methods to evaluate working ability and quality of life in natalizumab-treated 
RRMS patients. Methods: A non-interventional study was performed in Germany. 
Patients treated with natalizumab for a maximum of three months prior to baseline 
were eligible for study participation. Demographic and occupational information 
was collected; DSS and EQ-5D-questionnaires were used. Data were collected at 
baseline, after 6 months and after 12 months. Main objective was to evaluate pro-
ductivity per year, by using the formula: (working hours per day*5 days per week*46 
working weeks a year) - (days absent from work*working hours per year). To assess 
health economic cost savings, productivity has been valued monetarily by calcu-
lating a daily rate of working costs. Subgroup analysis divides the study popula-
tion into employed, unemployed, patients with statutory sick pay and students. 
Analyses of variance and subsequent post hoc tests will be performed to identify 
subgroup differences. Results: Of 95 patients included by January 2014, 46.3% 
were employed. Average hours worked/day were 5.3 hours (employed: 6.5 hours); 
average number of days absent from work during the past half-year was 17.4 days 
(employed: 16.5 days). Calculated productivity per 6 months results in 569.6 hours 
(employed: 661.0), meaning 6,5540.40€ (employed: 7,634.55€ ) in monetarily valued 
productivity. ConClusions: This non-interventional study aimed at providing new 
insights in the therapy of RRMS patients treated with natalizumab. The study’s 
intention was to show how an increase in working hours in employed patients as 
well as a decrease in days absent from work can lead to an increase in productivity. 
Study was funded by Biogen Idec.
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objeCtives: Teriflunomide is a once-daily oral immunomodulator approved for 
relapsing–remitting MS. The phase 3 TENERE (NCT00883337) study comparing 
teriflunomide with subcutaneous interferon beta-1a (sc IFNβ -1a) did not meet its 
primary endpoint (superiority of teriflunomide vs sc IFNβ -1a on time to treatment 
failure) although there was no difference in annualized relapse rate between teriflu-
nomide 14 mg and sc IFNβ -1a. The objective of the current analysis was to compare 
patient treatment satisfaction of teriflunomide with that of sc IFNβ -1a. Methods: 
Randomized patients (n= 324) received once-daily teriflunomide 14 mg or 7 mg or 
sc IFNβ -1a three times per week; the study was completed 48 weeks after the last 
patient was randomized. Patient satisfaction with treatment was assessed as a 
secondary endpoint using the Treatment Satisfaction Questionnaire for Medication 
(TSQM) version 1.4, a validated generic questionnaire with scores for effective-
ness, side-effects, convenience, and global satisfaction. A mixed-effect model with 
repeated measures was used to analyze TSQM scores at Week 48. Magnitude of 
effects was assessed using effect size (ES), defined as the difference in treatment 
effect divided by standard deviation. The ES differences were ranked as follows: < 0.2, 
negligible; ≥ 0.2–< 0.5, small; ≥ 0.5–≤ 0.8, moderate; > 0.8, high. Results: At Week 48, 
TSQM values showed significantly better patient satisfaction in the teriflunomide 
14-mg group vs the IFNβ -1a group in three domains (side-effects, P< 0.0001; con-
venience, P< 0.0001; global satisfaction, P= 0.02), with no perceived difference on 
effectiveness (P= 0.28). High ES values favoring teriflunomide 14 mg vs IFNβ -1a were 
seen with side-effects (1.09) and convenience (1.81), with a smaller ES for global 
satisfaction (0.39). ConClusions: A significant and meaningful improvement in 
treatment satisfaction for teriflunomide 14 mg vs IFNβ -1a was observed with regards 
to side-effects, convenience, and global satisfaction, which may potentially improve 
treatment adherence and outcomes in clinical practice.
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objeCtives: Analyze real-life AED treatment sequencing in the UK using prescrip-
tion data from the Clinical Practice Research Datalink (CPRD), and compare it to 
the 2012 National Institute for Health and Care Excellence (NICE) clinical guide-
lines. Methods: Patients were included if they had an epilepsy diagnosis and an 
AED prescription between January, 2009 and January, 2014. Patients who entered the 
database untreated were followed from first AED prescription following an epilepsy 
diagnosis, for up to five lines of treatment until being censored at the end of reg-
istration, death, or end of data coverage. Follow-up time could differ substantially 
between patients. AED treatment changes were classified as add, switch, or stop. 
The number of patients per treatment line was calculated for each individual AED 
combination and each regimen, grouped as Monotherapy, Polytherapy, and “No 
AED”. Results: Overall, 8931 patients went through 2469 unique AED treatment 
sequences; 97.1% were started on Monotherapy. 30.8% of patients stayed on their 
first Monotherapy until censored. 16.5% of initial Monotherapy patients switched 
to a second Monotherapy; 27% went to “No AED”; 25.7% progressed to Polytherapy. 
The first treatment line was consistent with NICE guidelines for 70.4% of patients. 
Thereafter, 14.7% of patients were treated within guidelines in the first 2 lines. 
The main divergence from guidelines involved prescribing Polytherapy or “No 
AED” rather than a second monotherapy in line 2. Largely consistent with NICE, 
the most frequent (87.1%) initial monotherapy AEDs were valproic acid (30.1%), 
lamotrigine (22.8%), carbamazepine (17.5%), levetiracetam (10.3%), and phenytoin 
loss and resource were similar in Brazil and the 5EU (all p> 0.05). After adjustments 
(combined 5EU and Brazil), as the number of seizures decreased, PCS (≥ 1 seizures/
week: 40.9; 1-3 seizures/month: 41.7; 1-4 seizures/year: 46.9; < 1seizures/year: 48.4) 
and health utilities (≥ 1 seizures/week: 0.58; 1-3 seizures/month: 0.63; 1-4 seizures/
year: 0.63; < 1seizures/year: 0.69) increased. As the number of seizures decreased, 
activity impairment (≥ 1 seizures/week: 58.6%; 1-3 seizures/month: 51.1%; 1-4 sei-
zures/year: 35.7%; < 1seizures/year: 25.5%), emergency room visits and hospitaliza-
tions decreased. In Europe direct and indirect costs were highest for the ≥ 1 seizure/
week group. ConClusions: POS burden was similar in Europe and Brazil. As the 
number of seizures increased, economic and humanistic burden increased. Even 
with the large number of treatment options available, patients and the health care 
system need additional choices to reduce the frequency of seizures.
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objeCtives: Mobility impairments affect most multiple sclerosis (MS) patients 
(93%), yet many patients (~40%) “rarely or never” discuss trouble walking with a 
health care provider (HCP). To facilitate patient-HCP dialogue and early identifica-
tion of mobility impairments, the Early Mobility Impairment Questionnaire (EMIQ) 
was developed based on qualitative research with patients diagnosed with MS and 
in collaboration with key opinion leaders. To minimize the burden associated with 
administration of the EMIQ, psychometric analyses were applied to the initial draft 
to produce a parsimonious yet robust instrument. Methods: The EMIQ’s psycho-
metric performance was evaluated in a multi-center, prospective, observational 
study in subjects with an Expanded Disability Status Scale (EDSS) score of 2.0 to 
6.0. Iterative exploratory factor analysis (EFA) was used to guide item reduction; 
subsequently, an item response theory (IRT) graded response model was applied to 
confirm the robustness of the instrument. Logistic regression analyses (using EDSS 
scores) were used to confirm discriminatory power. Results: In total, 124 subjects 
with moderate MS (EDSS mean score = 4.2) were included in the study. Discriminant 
validity, factor analysis, and IRT modeling identified six items for reduction. The 
resulting 9-item scale had one strong underlying domain (first eigenvalue explained 
60% of variance). The information curve showed sufficient sensitivity (I> 3.3 for 
-2.6≤ θ ≤ 2.4) throughout the scale (mild to severe), with the most precise informa-
tion provided at ½ SD above the mean (I= 12 at θ = 0.4). Logistic regression showed 
that the EMIQ was able to discriminate between patients with and without walk-
ing impairment (p< 0.05). ConClusions: The psychometric analyses resulted in a 
streamlined scale that is appropriate for the screening of subjects experiencing early 
mobility impairments due to MS. In addition to a potential role in guiding clinical 
assessment and intervention, the EMIQ may also prove useful in the longitudinal 
assessment of mobility, as patients’ conditions decline.
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objeCtives: The impact of Cognitive Impairment (CI) on Health Related Quality 
of Life (HRQoL) in patients with Relapsing Remitting Multiple Sclerosis (RRMS) 
is becoming a field of study increasingly relevant due to its implications on the 
effectiveness and quality research. Since the studies reviewed highlight contra-
dictory results, the aim of this study was to determine the predictive value of CI 
and other correlated factors on HRQoL in a sample of RRMS patients. Methods: 
Observational, cross-sectional and multicenter study at 21 Neurology Departments 
in Spain. Multiple linear regression analysis (stepwise) was carried out to 
assess if HRQoL (EQ-5D scores) was predicted by CI (Brief Repeatable Battery of 
Neuropsychological Tests, BRB-N), physical disability (Expanded Disability Status 
Scale -EDSS), depression (Beck Depression Inventory-BDI-II) and disease duration 
(years diagnosed). Bivariate, partial and semi-partial correlations and multicol-
linearity analysis were performed to control confounding factors. Results: We 
included 291 RRMS patients (71.50% female), mean age 41.65 years (SD= 10.18). The 
mild disability group (EDSS 0-3) included 152 (52.20%) patients and the moder-
ate disability group (EDSS 3.5-5.5) included 139 patients (47.80%). All correlations 
between EQ-5D scores and BRB-N, BDI-II, EDSS and disease duration variables were 
statistically significant (p< 0.01), not multicollinearity detected. The results of the 
regression analysis indicated that two predictors explained 56.9% of the HRQoL 
variance (Adjusted R squared= 0.569, F= 187,251, p< 0.01). It was found that depres-
sion significantly predicted HRQoL (Beta= -0.587, p< 0.01), as did physical disability 
(Beta= -0.315, p< 0.01). ConClusions: The results showed a weak predictive value 
of CI (measured with the BRB-N battery) in HRQOL scores while depression and 
psychical disability were important predictors. Future research is needed in order 
to clarify the relationship between CI and HRQoL.
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objeCtives: Relapsing remitting multiple sclerosis (RRMS) is a chronic inflam-
matory disease representing the most common chronic neurological disorder in 
young adults. RRMS usually leads to permanent disability and as a result is a major 
cause of reduced working capacity due to neurological diseases. This abstract pre-
